Report cover image

Plasma Protease C1-Inhibitor Global Market Report 2025

Publisher The Business Research Company
Published Jul 07, 2025
Length 175 Pages
SKU # BRC20166170

Description

Plasma Protease C1-Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on plasma protease c1-inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.
Description:

Where is the largest and fastest growing market for plasma protease c1-inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The plasma protease c1-inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:1) By Drug Class: C1-Inhibitors; C1-Esterase Inhibitor; Recombinant Inhibitor; Kallikrein Inhibitor; Selective Bradykinin B2 Receptor Antagonist

2) By Dosage Form: Lyphophlised; Injectables

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By C1-Inhibitors: Plasma-Derived C1-Inhibitor; Recombinant C1-Inhibitor

2) By C1-Esterase Inhibitor: Intravenous (IV) C1-Esterase Inhibitor; Subcutaneous (SC) C1-Esterase Inhibitor

3) By Recombinant Inhibitor: Recombinant Human C1-Inhibitor; Recombinant Analog Inhibitor

4) By Kallikrein Inhibitor: Plasma Kallikrein Inhibitor; Oral Kallikrein Inhibitor

5) By Selective Bradykinin B2 Receptor Antagonist: Injectable B2 Receptor Antagonist; Oral B2 Receptor Antagonist

Companies Mentioned: Takeda Pharmaceutical Company Limited; CSL Behring LLC; Sigma-Aldrich Co. LLC; Octapharma AG; Bio-Techne Corp

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Table of Contents

175 Pages
1. Executive Summary
2. Plasma Protease C1-Inhibitor Market Characteristics
3. Plasma Protease C1-Inhibitor Market Trends And Strategies
4. Plasma Protease C1-Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Plasma Protease C1-Inhibitor Growth Analysis And Strategic Analysis Framework
5.1. Global Plasma Protease C1-Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Plasma Protease C1-Inhibitor Market Growth Rate Analysis
5.4. Global Plasma Protease C1-Inhibitor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Plasma Protease C1-Inhibitor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Plasma Protease C1-Inhibitor Total Addressable Market (TAM)
6. Plasma Protease C1-Inhibitor Market Segmentation
6.1. Global Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
C1-Inhibitors
C1-Esterase Inhibitor
Recombinant Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
6.2. Global Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lyphophlised
Injectables
6.3. Global Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of C1-Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Plasma-Derived C1-Inhibitor
Recombinant C1-Inhibitor
6.5. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of C1-Esterase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous (IV) C1-Esterase Inhibitor
Subcutaneous (SC) C1-Esterase Inhibitor
6.6. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Recombinant Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Recombinant Human C1-Inhibitor
Recombinant Analog Inhibitor
6.7. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Plasma Kallikrein Inhibitor
Oral Kallikrein Inhibitor
6.8. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injectable B2 Receptor Antagonist
Oral B2 Receptor Antagonist
7. Plasma Protease C1-Inhibitor Market Regional And Country Analysis
7.1. Global Plasma Protease C1-Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Plasma Protease C1-Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Plasma Protease C1-Inhibitor Market
8.1. Asia-Pacific Plasma Protease C1-Inhibitor Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Plasma Protease C1-Inhibitor Market
9.1. China Plasma Protease C1-Inhibitor Market Overview
9.2. China Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Plasma Protease C1-Inhibitor Market
10.1. India Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Plasma Protease C1-Inhibitor Market
11.1. Japan Plasma Protease C1-Inhibitor Market Overview
11.2. Japan Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Plasma Protease C1-Inhibitor Market
12.1. Australia Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Plasma Protease C1-Inhibitor Market
13.1. Indonesia Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Plasma Protease C1-Inhibitor Market
14.1. South Korea Plasma Protease C1-Inhibitor Market Overview
14.2. South Korea Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Plasma Protease C1-Inhibitor Market
15.1. Western Europe Plasma Protease C1-Inhibitor Market Overview
15.2. Western Europe Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Plasma Protease C1-Inhibitor Market
16.1. UK Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Plasma Protease C1-Inhibitor Market
17.1. Germany Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Plasma Protease C1-Inhibitor Market
18.1. France Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Plasma Protease C1-Inhibitor Market
19.1. Italy Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Plasma Protease C1-Inhibitor Market
20.1. Spain Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Plasma Protease C1-Inhibitor Market
21.1. Eastern Europe Plasma Protease C1-Inhibitor Market Overview
21.2. Eastern Europe Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Plasma Protease C1-Inhibitor Market
22.1. Russia Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Plasma Protease C1-Inhibitor Market
23.1. North America Plasma Protease C1-Inhibitor Market Overview
23.2. North America Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Plasma Protease C1-Inhibitor Market
24.1. USA Plasma Protease C1-Inhibitor Market Overview
24.2. USA Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Plasma Protease C1-Inhibitor Market
25.1. Canada Plasma Protease C1-Inhibitor Market Overview
25.2. Canada Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Plasma Protease C1-Inhibitor Market
26.1. South America Plasma Protease C1-Inhibitor Market Overview
26.2. South America Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Plasma Protease C1-Inhibitor Market
27.1. Brazil Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Plasma Protease C1-Inhibitor Market
28.1. Middle East Plasma Protease C1-Inhibitor Market Overview
28.2. Middle East Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Plasma Protease C1-Inhibitor Market
29.1. Africa Plasma Protease C1-Inhibitor Market Overview
29.2. Africa Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Plasma Protease C1-Inhibitor Market Competitive Landscape And Company Profiles
30.1. Plasma Protease C1-Inhibitor Market Competitive Landscape
30.2. Plasma Protease C1-Inhibitor Market Company Profiles
30.2.1. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
30.2.2. CSL Behring LLC Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Sigma-Aldrich Co. LLC Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Octapharma AG Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Bio-Techne Corp Overview, Products and Services, Strategy and Financial Analysis
31. Plasma Protease C1-Inhibitor Market Other Major And Innovative Companies
31.1. Ionis Pharmaceuticals Inc.
31.2. Sanquin
31.3. Biotest AG
31.4. BioCryst Pharmaceuticals Inc.
31.5. Pharming Group N.V.
31.6. Sino Biological Inc
31.7. Cayman Chemical
31.8. Enzo Life Sciences Inc
31.9. KalVista Pharmaceuticals Inc.
31.10. Santa Cruz Biotechnology Inc
31.11. Pharvaris N.V
31.12. Attune Pharmaceuticals Inc.
31.13. Biorbyt Ltd
31.14. Adverum Biotechnologies Inc
31.15. Lev Pharmaceuticals
32. Global Plasma Protease C1-Inhibitor Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Plasma Protease C1-Inhibitor Market
34. Recent Developments In The Plasma Protease C1-Inhibitor Market
35. Plasma Protease C1-Inhibitor Market High Potential Countries, Segments and Strategies
35.1 Plasma Protease C1-Inhibitor Market In 2029 - Countries Offering Most New Opportunities
35.2 Plasma Protease C1-Inhibitor Market In 2029 - Segments Offering Most New Opportunities
35.3 Plasma Protease C1-Inhibitor Market In 2029 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us